Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Nintedanib, Idarubicin Hydrochloride, and Cytarabine in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia

This phase I / II trial studies the side effects of nintedanib, idarubicin hydrochloride, and cytarabine and to see how well they work in treating patients with acute myeloid leukemia that has come back or does not respond to treatment. Nintedanib may stop the growth of tumor cells by blocking the growth of new blood vessels necessary for tumor growth. Drugs used in chemotherapy, such as idarubicin hydrochloride and cytarabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nintedanib, idarubicin hydrochloride, and cytarabine may work better in treating patients with acute myeloid leukemia.
Leukemia
Phase I/II
Adults
Chemotherapy - cytotoxic, Mol. targeted/Immunotherapy/Biologics
Blinded Drug, Cytarabine (ARA-C), Idarubicin, Nintedanib
Strickland, Stephen
National
Vanderbilt University
03-15-2018
Treatment
VICCHEM1689
NCT02665143

Eligibility

18 Years
BOTH
NO
Inclusion Criteria:

Diagnosis of AML according to World Health Organization (WHO) 2008 criteria; therapy related AML may be included if in complete response and off treatment for their prior malignancy for more than 2 years; AML arising after documented myeloproliferative disease (MPD) are excluded

Patient must meet one of the following criteria: * Patient refractory to one or two standard induction regimen * Patients with a first untreated relapse within 2 years of documentation of clinical remission; patients relapsing after allogeneic stem cell transplantation are eligible if more than 6 months after transplantation and without sign of active graft versus host disease (GVHD)

Patient may have been pretreated with intermediate to high dose cytarabine (more than 1000mg/m2/d over 5d) if the day of the last infusion was at least 90 days before inclusion in the study

Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less

Patient is willing to participate to the study, has the ability to adhere to the study visit schedule and other protocol procedures, and has the ability to understand and signs an informed consent form

Women of childbearing potential must agree to use effective contraception without interruption throughout the study and for a further 3 months after the end of treatment

Men must agree to not conceive during the treatment and to use effective contraception during the treatment period (including periods of dose reduction or temporary suspension) and for a further 3 months after the end of treatment if their partner is of childbearing potential



Exclusion Criteria:

Patient with documented acute promyelocytic leukemia (PML) and/or PML- retinoic acid receptor (RAR) transcript

Patient relapsing more than 2 years after initial remission

Use of any active treatment for relapse/refractory AML including but not restricted to chemotherapy, targeted agents, hypomethylating agents or investigational drugs; use of hydroxyurea up to 6g per day for cytoreduction is allowed for a maximum of 30 days prior treatment

Patients with clinical evidences of active central nervous system (CNS) disease at inclusion

Left ventricular ejection fraction (LVEF) below 45% or lifetime exposure to anthracyclines over 350mg/m2 of daunorubicin equivalent

Aspartate aminotransferase (AST), alanine aminotransferase (ALT) above 2.5 upper limit of normal (ULN)

Total bilirubin above 2.5 ULN in the absence of hemolysis or diagnosis of Gilbert’s syndrome

Serum creatinine above 2.0mg/dl

Any sign of active uncontrolled disease including but not restricted to cardiac disease, infections, hepatitis; any severe chronic disease potentially interfering with the protocol including human immunodeficiency virus (HIV) infection, active hepatitis B or C; it includes major injuries and/or surgery within the past 4 weeks prior to start of study treatment with incomplete wound healing and/or planned surgery during the on-treatment study period

Documented platelet refractoriness

Patient has a history of gastrointestinal (GI) surgical procedures, non-surgical procedures or conditions that might interfere with the absorption or swallowing of the study drugs

Women who are pregnant, or who are currently breastfeeding

Prior treatment with nintedanib or any other vascular endothelial growth factor receptor (VEGFR) inhibitor, with the exception of treatment of prior malignancies with a VEGFR inhibitor

Known hypersensitivity to nintedanib, any other trial drug, or their excipients

Persistence of any clinically relevant (Common Terminology Criteria for Adverse Events [CTCAE] grade 2 or above) toxicities from previous AML therapy

Active alcohol or drug abuse

Any other condition that, according to the investigator, may forbid the administration of the idarubicin + cytarabine regimen

Therapeutic anticoagulation with international normalized ratio (INR) modifying drug of or use of antiplatelet therapy (with the exception of low dose aspirin
Any other malignancies requiring active treatment within the past year other than basal cell skin cancer or carcinoma in situ of the cervix; patients actively treated with hormonotherapy for prostate cancer or breast cancer are eligible

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: